Furthermore, RTX therapy could improve cutaneous lesions in atopic eczema patients through reducing IL-5 mRNA expression and IL-5-expressing CD4+ T-cell numbers in the skin, lowering Th2 frequencies and eosinophil counts in the blood [48,49]. This evidence concerns the gene IL5 and atopic eczema.